- Gilead Sciences Inc GILD has agreed to acquire MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors.
- Gilead will pay approximately $405 million in cash.
- The acquisition will provide Gilead with MiroBio's proprietary discovery platform and the entire portfolio of immune inhibitory receptor agonists.
- Related: Gilead Sciences' Q2 Beats Street View On Robust Oncology, HIV Product Sales.
- MiroBio's lead investigational antibody, MB272 has entered Phase 1 clinical trials, with the first patient dosed earlier this week.
- MiroBio's I-ReSToRE platform has the potential to be used to develop best-in-class agonist antibodies targeting immune inhibitory receptors for inflammatory diseases.
- The company expects the transaction with MiroBio to reduce Gilead's GAAP and non-GAAP 2022 EPS by approximately $0.30-$0.35.
- Price Action: GILD shares are up 0.42% at $62.01 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
